Another study focused on HR+/HER2- BC patients with T1c-T3 disease showed that the combination of Alpelisib with 24-week neoadjuvant letrozole treatment could not significantly improve patients’ responses (65). The gene discussed is ERBB2; the disease is breast cancer.